


Abstract

The invention provides a drug which inhibits BCRP.

A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1):



(1)

[wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (-NHCOCH₃ group), a cyano group (-CN group), a formyl group (-CHO group), -COOR₁ (R₁ is hydrogen or C1-C4 alkyl), -O(CH₂)_nCOOR₂ (n=1-7: R₂ is hydrogen or C1-C4 alkyl), -OOCCH₂CH₂COOR₃ (R₃ is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., -OP(O)(OH)₂) or a salt thereof, a sulfate group (i.e., -OSO₃H) or a salt thereof, a glycopyranosyl group or a salt thereof, a

phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.